CMS Issues Guidance on New Medicaid and CHIP Funding Limits for Noncitizens
CMS issued guidance implementing new limits on federal Medicaid and CHIP matching funds for certain noncitizens under Public Law 119-21 Section 71109. States must implement system changes by October 1, 2026, including updates to eligibility systems, applications, verification, and claims processing. Exceptions exist for emergency medical conditions and coverage of lawfully residing children and pregnant women.
Nalpac Issues Voluntary Nationwide Recall of DTF Sexual Chocolate Due to Presence of Undeclared Sildenafil and Tadalafil
Nalpac voluntarily recalls DTF Sexual Chocolate nationwide after FDA testing detected undeclared sildenafil and tadalafil, the active pharmaceutical ingredients in Viagra and Cialis. The recalled product (UPC 757817783069) was sold in adult retail stores and online through shopsexology.com and royalsins.com. Retailers must immediately remove the product from shelves, and consumers should stop using it and return or discard it, as the undeclared ingredients pose serious health risks, particularly for those taking nitrate medications.
DEA Detroit Public Safety Alert: Cychlorphine Synthetic Opioid Warning
DEA Detroit Division issued a public safety alert warning law enforcement, first responders, and medical professionals about Cychlorphine, a powerful synthetic opioid identified through DEA lab testing. The substance appears in powder form and has been found mixed into counterfeit pills, presenting serious risks including sedation, respiratory depression, and death.
DEA Houston Warns Counterfeit M30 Pills Contain Fentanyl
DEA Houston Division issued a public safety alert warning that counterfeit M30 pills (resembling oxycodone) seized during law enforcement operations have tested positive for fentanyl. The agency is urging the public not to use these pills as they pose a deadly risk and are part of the ongoing fentanyl crisis affecting communities.
SFDA, Saudi Innovation Club Sign Digital Transformation MoU
The Saudi Food and Drug Authority (SFDA) signed a Memorandum of Understanding with the Saudi Innovation Club to advance digital transformation. The agreement focuses on e-service development, user experience optimization, and knowledge exchange to enhance digital capabilities across both organizations. Key cooperation areas include joint programs to foster innovation culture and collaboration on sectors of mutual interest.
Walking-Working Surfaces Standard: Removal of Fixed Ladder Fall Protection Deadline
OSHA published a proposed rule in the Federal Register to remove a compliance deadline in the Walking-Working Surfaces standard requiring fixed ladders exceeding 24 feet to be equipped with personal fall arrest systems or ladder safety systems. The agency is simultaneously seeking public comment on whether to repeal or revise the underlying requirement entirely, potentially permitting employers to continue using ladder cages or wells instead of personal fall arrest systems.
OSHA Retaliation Complaints Information Collection OMB 1218-0236
OSHA is seeking public comments on its information collection request (OMB Control No. 1218-0236) regarding retaliation complaints filed under Section 11(c) of the OSH Act and related whistleblower protection statutes. The agency must obtain OMB approval to continue collecting information about employee complaints alleging retaliation for exercising safety and health rights. Comments are requested on whether the collection is necessary, the accuracy of burden estimates, and the quality of utility of the information.
Intertek Testing Services Expansion Application
OSHA has posted an expansion application from Intertek Testing Services in docket OSHA-2007-0039. Intertek, a Nationally Recognized Testing Laboratory (NRTL), is seeking to expand its OSHA-recognized testing scope. The application is available for public review and comment.
Intertek Testing Services Revised Expansion Application
OSHA posted Intertek Testing Services' revised expansion application for its Nationally Recognized Testing Laboratory (NRTL) program. The application pertains to expansion of testing and certification activities under the NRTL program's scope. This document is part of the administrative record for OSHA-2007-0039.
National Human Genome Research Institute Amends Meeting Notice
The National Human Genome Research Institute has amended a prior Federal Register meeting notice to modify the schedule for the National Advisory Council for Human Genome Research meeting. The open session is moved to May 18, 2026 from 10:00 a.m. to 5:00 p.m., with the closed session moved to May 19, 2026 from 10:00 a.m. to 1:00 p.m. A videocast link has also been added for the open session.
Center for Scientific Review Notice of Closed Meetings
The NIH Center for Scientific Review announces five closed meetings scheduled for May 1-4, 2026. These virtual meetings will review grant applications related to clinical neuroscience, hepatitis C vaccines, endocrinology, CTSA programs, and mental health conditions. Meetings are closed under the Federal Advisory Committee Act due to confidential trade secrets and personal privacy considerations.
Center for Scientific Review Notice of Closed Meetings
NIH Center for Scientific Review announces two closed virtual meetings scheduled for May 1, 2026. The meetings will review and evaluate grant applications for career development awards in social and community influences research, and chemical countermeasures against the nervous system. Both meetings are closed to the public under the Federal Advisory Committee Act to protect confidential trade secrets and personal information.
Interagency Autism Coordinating Committee Meeting Notice
NIH announces the Interagency Autism Coordinating Committee (IACC) will hold an open hybrid meeting on April 28, 2026, from 9:00 a.m. to 5:00 p.m. ET at the NIH campus in Bethesda, MD. The meeting will discuss committee business, updates, and autism research and services activities. Public comments are accepted through April 14, 2026.
Stakeholders consulted on Andrographis removal from permitted medicines
TGA proposes removing Andrographis from permitted medicines
Field Safety Notices: 30 March - 3 April 2026
MHRA published a weekly summary of Field Safety Notices received from medical device manufacturers for 30 March - 3 April 2026. The listing includes four FSNs: Abbott Afinion HbA1c diagnostic devices, Boston Scientific ACCOLADE cardiac devices, Ivoclar Vivadent Adhese 2 dental adhesives, and Resoundant Acoustic Driver System imaging devices. MHRA clarifies the listings are for information only and recommends contacting manufacturers directly with questions.
Spesolimab GPP flare prevention appraisal terminated, no evidence
NICE has terminated its appraisal of subcutaneous spesolimab (Spevigo) 1-ml formulation for preventing generalized pustular psoriasis flares in patients 12 years and older. The termination occurred because the manufacturer did not provide an evidence submission, leaving NICE unable to assess clinical effectiveness or cost-effectiveness. No NHS funding guidance will be issued for this indication.
Philips Azurion Interventional Radiology Recall, 847 Units
ANSM has recorded safety action R2603230 regarding Philips Azurion interventional radiology systems manufactured by Philips Medical Systems Nederland BV. Affected French healthcare facilities have received direct notification from Philips. The recall encompasses 847 units of the Azurion system. Healthcare providers should immediately review their inventory and contact Philips Medical Systems for corrective action.
WHO and France Launch One Health Initiatives at Lyon Summit
WHO and France hosted the One Health Summit in Lyon on World Health Day, announcing four major initiatives to operationalize the One Health approach linking human, animal, and environmental health. The Summit brings together global leaders to prevent future health crises, noting that 60% of known infectious diseases in humans originate from animals and 75% of emerging diseases are zoonotic. Outcomes will inform G7 discussions on health threat preparedness.
Medicare Advantage and Part D Program Changes for Contract Year 2027
CMS has published a final rule implementing comprehensive changes to Medicare Advantage (Part C), Medicare Prescription Drug Benefit (Part D), and Medicare cost plan regulations for contract year 2027. The rule codifies Inflation Reduction Act changes including the sunset of the Coverage Gap Discount Program and implementation of the new Manufacturer Discount Program, along with updates to Star Ratings, marketing standards, enrollment processes, and special needs plan requirements. The regulations are effective June 1, 2026 and apply to coverage beginning January 1, 2027.
Pink Pony Peptides - Unapproved New Drugs Warning
FDA issued a Warning Letter to Lovega LLC dba Pink Pony Peptides for marketing and selling unapproved new drugs, including peptide products GLP-2 TZ, GLP-3 RT, and Bacteriostatic Water. The products were found to be marketed with therapeutic claims despite labeling stating 'not for human consumption.' FDA determined the products meet the definition of new drugs under the FD&C Act and require approved applications before sale.
Prime Sciences Warning Letter - Unapproved New Drugs Sold Online
The FDA issued a warning letter to Prime Sciences (Scottsdale, AZ) for selling unapproved new drugs online through their website. The products at issue include Cagrilintide, GLP1-R (Retatrutide), GLP1-S (Semaglutide), GLP1-T (Tirzepatide), Mazdutide, and BAC water. These products are being marketed for human use in weight loss and diabetes management despite labeling that claims 'research purposes only' and 'not for human consumption.' The FDA determined these are unapproved new drugs under Section 505(a) of the FD&C Act.
Ehsan Sadri MD - FDA Warning Letter - Clinical Investigation Violations
FDA issued a Warning Letter to Dr. Ehsan Sadri, a clinical investigator, citing violations of 21 CFR 312.60 observed during an inspection of his clinical site in March-April 2025. The inspection, part of FDA's Bioresearch Monitoring Program, found that Dr. Sadri enrolled subjects who did not meet protocol-specified eligibility criteria, including missing required screening assessments and enrolling a subject with intraocular pressure outside the required range.
Global Tobacco LLC FDA warning, nicotine pouches
Global Tobacco LLC FDA warning, nicotine pouches
Warning Letter: Gram Peptides - Unapproved Retatrutide and Tirzepatide Sales
The FDA issued a Warning Letter to Gram Peptides and its owner Bernard Gramlich for marketing unapproved new drugs, specifically Retatrutide (labeled as "GLP-1-R peptide") and Tirzepatide (labeled as "GLP-2 peptide"), in violation of sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act. The agency determined these products are not generally recognized as safe and effective (GRASE) and are being sold with labeling that establishes intended use for human medical purposes despite "research use only" disclaimers.
Medline Industries LP - Quality System Regulation Violations Warning Letter
FDA issued a Warning Letter to Medline Industries, LP (NAMIC Division) citing Quality System Regulation violations under 21 CFR Part 820. The inspection conducted December 1-12, 2025 identified CAPA procedure failures involving NAMIC Angiographic Control Syringes that generated 221 complaints and 177 MDRs, including documented cases of air embolism patient harm and biohazard exposure to clinicians.
FDA Warning Letter to Guangzhou Huli Technology Co. Ltd. for Unapproved GLP-1 Drug Sales
The FDA's Center for Drug Evaluation and Research issued a Warning Letter to Guangzhou Huli Technology Co., Ltd. (dba Fantasy Face) on March 31, 2026, for selling unapproved new drugs through its eBay store. The company's 'Googeer GLP-1 Weight Control Oral Solution' is marketed as a weight loss and metabolism support product but lacks FDA approval under Section 505 of the FD&C Act. The FDA has demanded the company respond within 15 working days with corrective actions or face potential seizure and injunction.
Unapproved New Drugs - GLP-1/GIP/Glucagon Peptide Compounds
FDA issued a Warning Letter to Mile High Compounds LLC for marketing unapproved new drugs, including GLP-1 SM, GLP-2 TRZ, and GLP-3 RT peptide compounds, via their website. The agency determined these products are drugs under section 201(g)(1) of the FD&C Act because labeling and marketing materials make therapeutic claims for weight loss, addiction recovery, and metabolic control despite labeling disclaimers. The FDA cites violations of sections 301(d) and 505(a) of the FD&C Act for introducing unapproved drugs into interstate commerce.
Warning Letter - PekCura Labs - Unapproved GLP-1 Drugs Sold Online
FDA issued a Warning Letter to PekCura Labs (Pensacola, FL) on March 31, 2026, for selling unapproved new drugs including GLP-1-S, GLP-2-T, GLP-3-R, and Bacteriostatic Water through their website. The products are unapproved drugs under Section 505(a) of the FD&C Act, despite labeling claims that they are for 'research use only' and 'not for human consumption.' The FDA determined these injectable products pose serious public health risks because they bypass natural body defenses when delivered directly into the bloodstream.
18-year-old charged for alleged trafficking of etomidate vaporiser pods
HSA charged an 18-year-old male in Singapore court on 6 April 2026 for alleged trafficking of etomidate vaporiser pods. During an enforcement operation on 4 April, HSA officers seized 108 etomidate pods, one vaporiser, and duty-unpaid cigarettes. This is the second prosecution of an 18-year-old for etomidate trafficking, following enhanced penalties that took effect on 1 September 2025.